Updated recommendations of the International Dengue Initiative expert group for CYD-TDV vaccine implementation in Latin America

J. R. Torres, L. H. Falleiros-Arlant, B. D. Gessner, I. Delrieu, M. L. Avila-Aguero, H. I.G. Giambernardino, A. Mascareñas, J. Brea, C. N. Torres, J. M. Castellanos-Martinez, Antonio Arbo, Jose Geraldo Leite, José Luis Arrendondo, Eduardo López, María Luisa Avila, María Graciela López, Pablo F. Belaunzaran-Zamudio, Pío López, Miguel Betancourt Cravioto, Expedito LunaPablo Bonvehí, Alejandro Macías, Joao Bosco, Mercedes Macías, José Brea Del Castillo, Cristina Mariño, Gabriel Carrasquilla, Celia Martínez Cuellar, Martín Casapía, Jose Guadalupe Martínez, José Cassio De Moraes, Abiel Mascareñas, Javier Castellanos, Mario Melgar, Hector Castro, Duarte Edson Moreira, Carmen Deseda, Sarbelio Moreno, Miriam de Lourdes Dueñas, Juan Luis Mosqueda, José Esparza, Tomás Orduna, Jorge Falcón Lezama, Juan Miguel Pascale, Luiza Falleiros-Arlant, José Ramos Castañeda, Jacy Freire De Andrade, Nicolas Ramos, Bradford D. Gessner, Humberto Reynales, Norberto Giglio, Doris Rivera, Silvia González Ayala, Crisanta Rocha, Marte Hernández, Hernán Rodríguez, Heloisa Giambernardino, Doris Salgado, Delrieu Isabelle, Carlos Torres Martínez, Arnaldo Lachira, Jaime Torres Rojas

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

5 Citas (Scopus)

Resumen

Dengue disease represents a large and growing global threat to public health, causing a significant burden to health systems of endemic countries. For countries considering vaccination as part of their Integrated Management Strategy for Prevention and Control of Dengue, the World Health Organization currently recommends the first licensed dengue vaccine, CYD-TDV for: individuals aged 9 years or above from populations with high transmission rates, based on either seroprevalence criteria or pre-vaccination screening strategies, and for persons with confirmed prior exposure to infection in moderate to lower transmission settings. This paper describes the main conclusions of the Sixth Meeting of the International Dengue Initiative (IDI) held in June 2018, following release of a new product label by the manufacturer, updated WHO-SAGE recommendations, additional scientific evidence on vaccine performance, and reports of experiences by implementing countries. Considerations were made regarding the need for improving the quality of epidemiological and surveillance data in the region to help define the convenience of either of the two vaccination strategies recommended by WHO-SAGE. Extensive discussion was dedicated to the pros and cons of implementing either of such strategies in Latin America. Although, in general, a seroprevalence-based approach was preferred in high transmission settings, when cost-effectivity is favorable pre-vaccination screening is a convenient alternative. Cost-effectiveness evaluations can assist with the decisions by public health authorities of whether to introduce a vaccine. Where implemented, vaccine introduction should be part of a public health strategy that includes the participation of multiple sectors of society, incorporating input from scientific societies, ministries of heath, and civil society, while ensuring a robust communication program.

Idioma originalInglés
Páginas (desde-hasta)6291-6298
Número de páginas8
PublicaciónVaccine
Volumen37
N.º43
DOI
EstadoPublicada - 8 oct. 2019

Huella

Profundice en los temas de investigación de 'Updated recommendations of the International Dengue Initiative expert group for CYD-TDV vaccine implementation in Latin America'. En conjunto forman una huella única.

Citar esto